Efficacy of Lenvervimab, a Recombinant Human Immunoglobulin, in Treatment of Chronic Hepatitis B Virus Infection

Clin Gastroenterol Hepatol. 2020 Dec;18(13):3043-3045.e1. doi: 10.1016/j.cgh.2019.09.038.

Hye Won Lee ¹, Jun Yong Park ¹, Taegon Hong ², Min Soo Park ³, Sang Hoon Ahn ⁴

Affiliations

1 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea.
2 Department of Clinical Pharmacology, Yonsei University College of Medicine, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea.
3 Department of Clinical Pharmacology, Yonsei University College of Medicine, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea; Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea.
4 Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea; Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea; Yonsei Liver Center, Severance Hospital, Seoul, Korea; Clinical Trials Center, Severance Hospital, Seoul, Korea. Electronic address: [email protected].

PMID: 31589980 DOI: 10.1016/j.cgh.2019.09.038

Abstract

The mechanism of action of hepatitis B immunoglobulin (HBIG) for chronic hepatitis B (CHB) treatment is not fully understood. A clinical trial in Japan suggested that HBIG therapy might benefit patients with CHB.¹ Lenvervimab, a recombinant monoclonal HBIG developed by GC Pharma (Yongin, South Korea), has been screened from an anti-HBs-enriched phage-display library cloned from hepatitis B vaccine-boosted human blood cells and was produced in Chinese hamster ovary cells.^2-4.

Products

Cat. No.

Product Name

Description

Target

Research Area
HY-P99693

Lenvervimab

Hepatitis B Immunoglobulin

HBV

Infection

Name
Email *

	Sorry, but the email address you supplied was invalid.